ABBV-0805 Reduces Alpha-synuclein Clumping in Mice

ABBV-0805 Reduces Alpha-synuclein Clumping in Mice

311586

ABBV-0805 Reduces Alpha-synuclein Clumping in Mice

ABBV-0805, AbbVie’s experimental antibody-based therapy for Parkinson’s disease, selectively binds to toxic clumps of the alpha-synuclein protein — a hallmark of the disease — preventing their spread and prolonging survival in mouse models of Parkinson’s, a study shows. Also, the investigational antibody was found to bind to harmful alpha-synuclein forms in brains of deceased Parkinson’s patients. Based on these positive findings, ABBV-0805 is now in clinical development as a potential Parkinson’s treatment, the researchers noted.…

You must be logged in to read/download the full post.